Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature da ...

IMP761 is a first-in-class agonist LAG-3 antibody designed to restore balance to the immune system by enhancing the "brake” ...

Penn researchers have developed a platform that emulates human bone marrow’s native environment. This breakthrough addresses ...

The human body is composed of over 37 trillion cells , each with a limited lifespan. These cells are continuously replaced to maintain organ and ...

One reason that tonsils may grow back is that one of the operations to remove them is a partial tonsillectomy. Only removing ...

In today's fast-paced world, respiratory health is often neglected, especially for those suffering from chronic conditions ...

New York, USA, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...

FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing ...

F-FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing ...

RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from deadly lung diseases characterized by pulmonary inflammation, is pleased to announce ...

In separate, live virtual events, Vincent K. Lam, MD, and Chul Kim, MD, MPH, discuss molecular assays and treatment options for a patient with metastatic non–small cell lung cancer (NSCLC), with ...

9, 2025 — Researchers have shown that a test called ORACLE can predict lung cancer survival at the ... and enables fully automated analysis of tissue ... July 17, 2024 — A medication used ...